Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Ibritumomab tiuxetan |
Trade Name | Zevalin |
Synonyms | IDEC Y2B8 |
Drug Descriptions |
Zevalin (ibritumomab tiuxetan) is Yttrium-90 combined with the anti-CD20 antibody, rituximab, which may deliver radiation to tumor cells (PMID: 27497027). Zevalin (britumomab tiuxetan) is FDA approved for use in patients with low-grade or follicular B-cell non-Hodgkin's lymphoma (FDA.gov). |
DrugClasses | CD20 Antibody 24 |
CAS Registry Number | 206181-63-7 |
NCIT ID | C29981 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab | Ibritumomab tiuxetan Rituximab anti-thymocyte globulin | 0 | 1 |
Ibritumomab tiuxetan | Ibritumomab tiuxetan | 0 | 1 |
Ibritumomab tiuxetan + Rituximab | Ibritumomab tiuxetan Rituximab | 0 | 1 |